Last reviewed · How we verify
CAL/BDP Gel
CAL/BDP Gel is a Topical corticosteroid + vitamin D analogue combination Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Plaque psoriasis.
CAL/BDP Gel is a topical combination of calcipotriol (vitamin D analogue) and betamethasone dipropionate (corticosteroid) that reduces skin inflammation and normalizes keratinocyte differentiation.
CAL/BDP Gel is a topical combination of calcipotriol (vitamin D analogue) and betamethasone dipropionate (corticosteroid) that reduces skin inflammation and normalizes keratinocyte differentiation. Used for Plaque psoriasis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CAL/BDP Gel |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Drug class | Topical corticosteroid + vitamin D analogue combination |
| Target | Vitamin D receptor (VDR), glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol is a vitamin D3 analogue that regulates keratinocyte proliferation and differentiation, while betamethasone dipropionate is a potent corticosteroid that suppresses inflammatory cytokines and immune cell infiltration. Together, they provide synergistic anti-inflammatory and anti-proliferative effects on psoriatic plaques when applied topically.
Approved indications
- Plaque psoriasis
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAL/BDP Gel CI brief — competitive landscape report
- CAL/BDP Gel updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about CAL/BDP Gel
What is CAL/BDP Gel?
How does CAL/BDP Gel work?
What is CAL/BDP Gel used for?
Who makes CAL/BDP Gel?
What drug class is CAL/BDP Gel in?
What development phase is CAL/BDP Gel in?
What are the side effects of CAL/BDP Gel?
What does CAL/BDP Gel target?
Related
- Drug class: All Topical corticosteroid + vitamin D analogue combination drugs
- Target: All drugs targeting Vitamin D receptor (VDR), glucocorticoid receptor (GR)
- Manufacturer: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing